RNA Bull Call Spread Strategy
RNA (Atrium Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.
RNA (Atrium Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $208.2M, a beta of 0.37 versus the broader market, a 52-week range of 11.13-16.77, average daily share volume of 202K, a public-listing history dating back to 2026, approximately 511 full-time employees. These structural characteristics shape how RNA stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.37 indicates RNA has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a bull call spread on RNA?
A bull call spread buys an at-the-money call and sells an out-of-the-money call at a higher strike for defined risk and defined reward bounded by the strike width.
RNA snapshot
As of August 14, 2026, spot at $13.14, ATM IV 18.60%, IV rank 10.50%, expected move 5.33%. The bull call spread on RNA below is built from the August 14, 2026 end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 154-day expiry.
Why this bull call spread structure on RNA specifically: RNA IV at 18.60% is on the cheap side of its 1-year range, which favors premium-buying structures like a RNA bull call spread, with a market-implied 1-standard-deviation move of approximately 5.33% (roughly $0.70 on the underlying). The 154-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated RNA expiries trade a higher absolute premium for lower per-day decay. Position sizing on RNA should anchor to the underlying notional of $13.14 per share and to the trader's directional view on RNA stock.
RNA bull call spread setup
The RNA bull call spread below is built from the August 14, 2026 end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With RNA at $13.14 on that close, the first option leg uses a $13.14 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed RNA chain at a 154-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 RNA shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $13.14 | N/A |
| Sell 1 | Call | $13.80 | N/A |
RNA bull call spread risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit equals strike width minus net debit times 100; max loss equals net debit times 100. Breakeven is long-call strike plus net debit.
RNA bull call spread payoff curve
Modeled P&L at expiration across a range of underlying prices for the bull call spread on RNA. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use bull call spread on RNA
Bull call spreads on RNA reduce the cost of a bullish RNA stock position by selling a higher-strike call; suited to moderate-move theses where price reaches but does not vastly exceed the short strike.
RNA thesis for this bull call spread
The market-implied 1-standard-deviation range for RNA extends from approximately $12.44 on the downside to $13.84 on the upside. A RNA bull call spread caps both the risk and the reward of a bullish position; relative to an outright long call on RNA, the spread reduces the cost basis but limits the maximum profit to the strike width minus net debit. Current RNA IV rank near 10.50% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on RNA at 18.60%. As a Healthcare name, RNA options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to RNA-specific events.
RNA bull call spread positions are structurally moderately bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. RNA positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move RNA alongside the broader basket even when RNA-specific fundamentals are unchanged. Long-premium structures like a bull call spread on RNA are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current RNA chain quotes before placing a trade.
Frequently asked questions
- What is a bull call spread on RNA?
- A bull call spread on RNA is the bull call spread strategy applied to RNA (stock). The strategy is structurally moderately bullish: A bull call spread buys an at-the-money call and sells an out-of-the-money call at a higher strike for defined risk and defined reward bounded by the strike width. With RNA stock at $13.14 on the August 14, 2026 close, the strikes shown on this page are snapped to the nearest listed RNA chain strike and the premiums come straight from that session's bid/ask midpoint.
- How are RNA bull call spread max profit and max loss calculated?
- Max profit equals strike width minus net debit times 100; max loss equals net debit times 100. Breakeven is long-call strike plus net debit. For the RNA bull call spread priced from the August 14, 2026 end-of-day chain at a 30-day expiry (ATM IV 18.60%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a RNA bull call spread?
- The breakeven for the RNA bull call spread priced on this page is no defined breakeven on the modeled curve at expiration, derived from the August 14, 2026 end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The RNA market-implied 1-standard-deviation expected move in the same options snapshot is approximately 5.33%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a bull call spread on RNA?
- Bull call spreads on RNA reduce the cost of a bullish RNA stock position by selling a higher-strike call; suited to moderate-move theses where price reaches but does not vastly exceed the short strike.
- How does current RNA implied volatility affect this bull call spread?
- RNA ATM IV is at 18.60% with IV rank near 10.50%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.